出典:Wikipedia
出典:『Wikipedia』 (2011/06/07 22:13 UTC 版)
MDV3100 is an experimental androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of hormone-refractory prostate cancer currently in Phase 3 clinical trials. Results so far have been encouraging; Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.